It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable
activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure …

Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs)
are tremendous, the design and discovery of new candidates remain a time and cost …

Despite recent advances in transgenic animal models and display technologies,
humanization of mouse sequences remains one of the main routes for therapeutic antibody …

Antibodies are versatile molecular binders with an established and growing role as
therapeutics. Computational approaches to developing and designing these molecules are …

Antibodies are proteins that recognize the molecular surfaces of potentially noxious
molecules to mount an adaptive immune response or, in the case of autoimmune diseases …

Monoclonal antibodies have emerged as key therapeutics. In particular, nanobodies, small,
single-domain antibodies that are naturally expressed in camelids, are rapidly gaining …

Therapeutic monoclonal antibodies and their derivatives are key components of clinical
pipelines in the global biopharmaceutical industry. The availability of large datasets of …

Motivation Monoclonal antibody (mAb) therapeutics are often produced from non-human
sources (typically murine), and can therefore generate immunogenic responses in humans …